$140,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1492/S.832 - EPIC Act. Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1492/S.832 - EPIC Act. Issues related to the Medicaid rebate. Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law."
You can find more data on corporate lobbying on Quiver Quantitative.
IONS Insider Trading Activity
IONS insiders have traded $IONS stock on the open market 57 times in the past 6 months. Of those trades, 1 have been purchases and 56 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 12 sales selling 216,005 shares for an estimated $13,811,605.
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 6 sales selling 207,843 shares for an estimated $12,482,827.
- RICHARD S GEARY (EVP, Chief Development Officer) has made 0 purchases and 3 sales selling 77,900 shares for an estimated $4,709,932.
- JOSEPH H WENDER has made 0 purchases and 7 sales selling 72,800 shares for an estimated $4,324,695.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 6 sales selling 61,625 shares for an estimated $3,837,493.
- JOSEPH III KLEIN has made 0 purchases and 2 sales selling 56,000 shares for an estimated $3,360,000.
- ELIZABETH L HOUGEN (EVP, Finance & CFO) sold 49,800 shares for an estimated $3,249,733
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 54,909 shares for an estimated $3,098,620.
- ERIC SWAYZE (EVP Research) has made 0 purchases and 5 sales selling 45,093 shares for an estimated $2,819,323.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) has made 0 purchases and 3 sales selling 29,207 shares for an estimated $1,604,121.
- B LYNNE PARSHALL has made 0 purchases and 4 sales selling 25,000 shares for an estimated $1,227,943.
- JOSEPH LOSCALZO sold 16,000 shares for an estimated $962,371
- MICHAEL R HAYDEN purchased 15,000 shares for an estimated $477,900
- SHANNON L. DEVERS (EVP, Chief Human Resources Ofc) sold 3,162 shares for an estimated $192,942
- ALLENE M. DIAZ sold 1,427 shares for an estimated $60,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IONS Hedge Fund Activity
We have seen 202 institutional investors add shares of IONS stock to their portfolio, and 164 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,724,400 shares (+253.3%) to their portfolio in Q2 2025, for an estimated $107,641,044
- ORBIMED ADVISORS LLC removed 2,540,136 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $100,360,773
- WELLINGTON MANAGEMENT GROUP LLP removed 2,070,645 shares (-24.6%) from their portfolio in Q2 2025, for an estimated $81,811,183
- MILLENNIUM MANAGEMENT LLC added 2,014,157 shares (+317.0%) to their portfolio in Q2 2025, for an estimated $79,579,343
- CITADEL ADVISORS LLC removed 1,985,081 shares (-57.0%) from their portfolio in Q2 2025, for an estimated $78,430,550
- NORGES BANK removed 1,264,508 shares (-73.7%) from their portfolio in Q2 2025, for an estimated $49,960,711
- POLAR CAPITAL HOLDINGS PLC added 1,000,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $39,510,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IONS Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 10 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 10/08/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/08/2025
- Morgan Stanley issued a "Overweight" rating on 09/23/2025
- BMO Capital issued a "Outperform" rating on 09/03/2025
- Goldman Sachs issued a "Sell" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 09/03/2025
- Needham issued a "Buy" rating on 09/02/2025
To track analyst ratings and price targets for IONS, check out Quiver Quantitative's $IONS forecast page.
IONS Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 19 analysts offer price targets for $IONS in the last 6 months, with a median target of $80.0.
Here are some recent targets:
- Jay Olson from Oppenheimer set a target price of $90.0 on 10/08/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $95.0 on 10/08/2025
- Jessica Fye from JP Morgan set a target price of $80.0 on 10/08/2025
- Joseph Stringer from Needham set a target price of $78.0 on 10/08/2025
- Paul Matteis from Stifel set a target price of $67.0 on 10/06/2025
- Salveen Richter from Goldman Sachs set a target price of $65.0 on 09/26/2025
- Michael Ulz from Morgan Stanley set a target price of $86.0 on 09/23/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
